Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Children's Hospital of Fudan University | Tongji Hospital | Children's Hospital of Nanjing Medical University | Jiangxi Province Children's Hospital | Chengdu Women's and Children's Central Hospital | Shandong Provincial Hospital | Shengjing Hospital | Sh
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Recombinant Human Growth Hormone is a Hormone drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Achondroplasia.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
April 29, 2022
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Children's Hospital of Fudan University | Tongji Hospital | Children's Hospital of Nanjing Medical University | Jiangxi Province Children's Hospital | Chengdu Women's and Children's Central Hospital | Shandong Provincial Hospital | Shengjing Hospital | Sh
Deal Size : Inapplicable
Deal Type : Inapplicable